<?xml version="1.0" encoding="UTF-8"?>

<rootTag>
  <Award>
    <AwardTitle>SBIR Phase II: Suction Retention Smart Variable Geometry Sockets (SVGS) for Transtibial Prostheses</AwardTitle>
    <AwardEffectiveDate>06/01/2001</AwardEffectiveDate>
    <AwardExpirationDate>05/31/2005</AwardExpirationDate>
    <AwardAmount>805988</AwardAmount>
    <AwardInstrument>
      <Value>Standard Grant</Value>
    </AwardInstrument>
    <Organization>
      <Code>07070000</Code>
      <Directorate>
        <LongName>Directorate For Engineering</LongName>
      </Directorate>
      <Division>
        <LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
      </Division>
    </Organization>
    <ProgramOfficer>
      <SignBlockName>F.C. Thomas Allnutt</SignBlockName>
    </ProgramOfficer>
    <AbstractNarration>This Small Business Innovation Research (SBIR) Phase II project will complete development of a production Smart Variable Geometry Socket (SVGS) for transtibial amputees (TTAs) and will test it with a clinical study. This non-electrical system is a simple means for ensuring and maintaining a good socket fit, with security and stability increased over the state of the art. Poorly fitting sockets, which cause pain and skin lesions, are responsible for a significant portion of TTAs rejecting a prosthesis. The SVGS/TT utilizes suction retention, which provides an important benefit, particularly to diabetics, by increasing blood circulation in the residual limb.&lt;br/&gt;&lt;br/&gt;The unique SVGS system consists of multiple, liquid-filled bladders placed by the prosthetist during socket fitting and a control for maintaining appropriate pressures on the residual limb at selected locations, all contained within the dimensions of a conventional prosthesis. The SVGS can be applied by the prosthetist with existing equipment and conventional art, thereby minimizing implementation cost. This attribute will enhance market acceptance. Phase I demonstrated feasibility; Phase II will measure efficacy and acceptance by TTAs. Phase II results will be the catalyst for successful commercialization.</AbstractNarration>
    <MinAmdLetterDate>05/18/2001</MinAmdLetterDate>
    <MaxAmdLetterDate>05/25/2004</MaxAmdLetterDate>
    <ARRAAmount/>
    <AwardID>0091513</AwardID>
    <Investigator>
      <FirstName>Richard</FirstName>
      <LastName>Greenwald</LastName>
      <EmailAddress>rgreenwald@simbex.com</EmailAddress>
      <StartDate>05/18/2001</StartDate>
      <EndDate/>
      <RoleCode>Principal Investigator</RoleCode>
    </Investigator>
    <Institution>
      <Name>SIMBEX LLC</Name>
      <CityName>LEBANON</CityName>
      <ZipCode>037661604</ZipCode>
      <PhoneNumber>6034482367</PhoneNumber>
      <StreetAddress>10 WATER ST STE 410</StreetAddress>
      <CountryName>United States</CountryName>
      <StateName>New Hampshire</StateName>
      <StateCode>NH</StateCode>
    </Institution>
    <FoaInformation>
      <Code>0116000</Code>
      <Name>Human Subjects</Name>
    </FoaInformation>
    <FoaInformation>
      <Code>0203000</Code>
      <Name>Health</Name>
    </FoaInformation>
  </Award>
</rootTag>
